The role of VSNL1 in human heart rate regulation
VSNL1在人体心率调节中的作用
基本信息
- 批准号:10750747
- 负责人:
- 金额:$ 8.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-30 至 2025-09-29
- 项目状态:未结题
- 来源:
- 关键词:Action PotentialsAdrenergic AgentsAdrenergic AgonistsAdrenergic ReceptorAdrenergic beta-AntagonistsAffectAgonistArrhythmiaAtrial FunctionAttenuatedAutonomic nervous systemBiologicalBradycardiaCRISPR/Cas technologyCalciumCardiac conduction systemCardiovascular PhysiologyCardiovascular systemCell LineCell modelCell physiologyCellsCellular biologyCentral Nervous SystemCharacteristicsCholinergic AgonistsClinicalDataDerivation procedureDevelopmentElectrocardiogramElectrophysiology (science)EndocrineEtiologyExerciseGene Expression ProfilingGenerationsGenetic DatabasesGenetic EngineeringGenomicsGoalsHealthHeartHeart AtriumHeart RateHumanHuman ActivitiesIn VitroIndividualKnock-inKnock-outLeadLongevityMagnetic Resonance ImagingMapsMendelian randomizationMethodologyMethodsModelingMolecularMolecular ProfilingMorbidity - disease rateMuscle CellsNervous SystemNeurotransmitter ReceptorNeurotransmittersNodalOutcomePacemakersParticipantPatternPeriodicityPhenotypePhysiologicalPhysiologyPopulation GeneticsPrecision therapeuticsPrincipal InvestigatorProteinsProteomicsProtocols documentationRegulationReporterRestRoleSecondary toSignal PathwaySignal TransductionSinoatrial NodeStimulusStress TestsSystemTachycardiaTechnologyTestingTimeVSNL1 geneValidationVariantVentricularVentricular Functionbiobankcardiac magnetic resonance imagingcardiovascular effectscell typecholinergicclinical databaseclinical phenotypecohortdesigndifferentiation protocolembryonic stem cellepidemiology studygain of functiongenetic varianthuman datahuman embryonic stem cellhuman embryonic stem cell linein vitro Modelloss of functionmortalitynew therapeutic targetnodal myocytenull mutationparacrinepatch clampresponsesensorsingle-cell RNA sequencingstem cellstooltraffickingtranscriptomics
项目摘要
PROJECT SUMMARY
In the heart, pacemakers or sinoatrial node cells (SAN) initiate and maintain a rhythmic beating pattern that can
respond to external stimuli, including neurotransmitters, paracrine, and endocrine signals. In addition to its
clinical importance, resting heart rate is associated with lifespan across species, and has strong correlation with
longevity within individuals in several large epidemiologic studies. Despite their key role in human health and
physiology, the exact intracellular mechanism to maintain precise rhythmic oscillation is unknown, given the
limited access to these cells in the heart. The principal investigator hypothesizes that gene expression
analysis of the human sinoatrial node cell will identify cellular and physiologic features of human
pacemaking function. Recent technologies have enabled generating functional human SAN from embryonic
stem cells (hPSC-SAN) and performing molecular characterization at the single cell level. VSNL1, a calcium
sensing protein, was identified as a marker specific to SAN cells. I hypothesize that VSNL1 is uniquely
involved in heart rate regulation. Analyzing the genetic variants in VSNL1 gene and their effect on heart rate
in large biobanks will enable validation of the functional role of this protein in heart rate physiology. The applicant
will use large biobank cohorts and genetically engineered human embryonic stem cells to pursue the following
aims: First, determine the association between genetic variants in VSNL1 with cardiovascular physiology in
several large biobanks. Preliminary data in UK biobank (UKBB) cohort suggests significant association between
genetic variants in VSNL1 gene and baseline heart rate. The applicant will further study the effect of VSNL1
variants on heart rate with exercise, atrial and ventricular function (on cardiac MRI), and cardiovascular morbidity
and mortality outcomes in UKBB and other more diverse cohorts. Second, understand the effect of genetic
variants associated with heart rate in UKBB on molecular and electrophysiological characteristics of hPSC-SAN
cells in vitro. In preliminary data, the applicant has successfully confirmed the specific expression of VSNL1 in
hPSC-SAN cells and their absence in the human embryonic stem cells (hESC) derived ventricular myocytes.
Using CRISPR-Cas9 technology, the applicant has generated knock-out models of VSNL1 gene in hESC. The
applicant will use hESC lines carrying VSNL1 null mutation to generate hPSC-SAN lacking functional VSNL1.
Analyzing beating rate, calcium activity, and action potential using patch clamp will elucidate the cell type-specific
role of VSNL1 in human SAN biology. Third, perform functional studies to test the role of VSNL1 in hPSC-SAN
response to adrenergic and cholinergic signals. Recent studies support that VSNL1 is involved in
neurotransmitter receptor trafficking. The applicant will generate loss of function (LoF) and gain of function (GoF)
VSNL1 variants in hESC using the previously established protocols. The applicant will generate SAN cells from
hESCs carrying knock-out, GoF, or LoF VSNL1 variants to study the effect of various adrenergic and cholinergic
neurotransmitters on SAN cells’ beating rate, calcium, activity, and action potential.
项目总结
在心脏,起搏器或窦房结细胞(SAN)启动并维持一种有节奏的搏动模式,这种模式可以
对外界刺激做出反应,包括神经递质、旁分泌和内分泌信号。除了它的
临床重要性,静息心率与不同物种的寿命相关,并与
几项大型流行病学研究中的个体寿命。尽管它们在人类健康中起着关键作用
生理学方面,维持精确节律振荡的确切细胞内机制尚不清楚,因为
限制进入心脏中的这些细胞。首席研究人员假设基因表达
对人类窦房结细胞的分析将确定人类的细胞和生理特征
起搏功能。最近的技术已经能够从胚胎中产生具有功能的人类SAN
干细胞(hPSC-SAN),并在单细胞水平上进行分子表征。钙离子VSNL1
传感蛋白被鉴定为窦房结细胞的特异性标志物。我假设VSNL1是唯一的
参与心率调节。VSNL1基因的遗传变异及其对心率的影响
在大型生物库中,将能够验证这种蛋白质在心率生理学中的功能作用。申请人
将使用大型生物库队列和经过基因工程的人类胚胎干细胞来追求以下目标
目的:首先,确定VSNL1基因变异与心血管生理学的关系
几个大型生物库。英国生物库(UKBB)队列的初步数据表明,
VSNL1基因的遗传变异与基线心率申请人将进一步研究VSNL1的影响
心率与运动、房室功能(心脏核磁共振)和心血管发病率的差异
以及UKBB和其他更多样化的队列中的死亡结果。第二,了解基因的影响
UKBB心率相关变异对hPSC-SAN分子和电生理特性的影响
体外培养的细胞。在初步数据中,申请人已成功确认VSNL1在
HPSC-SAN细胞及其在人胚胎干细胞(HESC)来源的心室肌细胞中的缺失。
利用CRISPR-Cas9技术,申请人已经建立了hESC中VSNL1基因的敲除模型。这个
申请者将使用携带VSNL1零突变的hESC系来产生缺乏功能VSNL1的hPSC-SAN。
使用膜片钳分析搏动频率、钙活性和动作电位将阐明细胞类型的特异性
VSNL1在人类窦房结生物学中的作用第三,进行功能研究,测试VSNL1在hPSC-SAN中的作用
对肾上腺素能和胆碱能信号的反应。最近的研究支持VSNL1参与
神经递质受体交易。申请人将产生功能损失(LoF)和功能增益(GoF)
使用先前建立的协议的hESC中的VSNL1变体。申请者将从以下位置生成SAN细胞
携带基因敲除、GoF或LoF VSNL1突变体的人胚胎干细胞研究各种肾上腺素能和胆碱能的作用
神经递质对窦房结细胞的搏动频率、钙离子、活性和动作电位的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZANIAR GHAZIZADEH其他文献
ZANIAR GHAZIZADEH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 8.08万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 8.08万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 8.08万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 8.08万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 8.08万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 8.08万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 8.08万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 8.08万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 8.08万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 8.08万 - 项目类别:














{{item.name}}会员




